Tradestie Institutional Equity Comparison Engine

PACB vs PMI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PMI Overall Edge

PMI Captures Institutional Edge (4โ€“0 Pillars ยท 6โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Picard Medical, Inc. (PMI) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, PACB trades at N/M Forward P/E with -333.0% operating margin (+5.5% YoY revenue) versus PMI at N/M Forward P/E and -248.1% operating margin (+38.6% YoY). In options structure, PACB sits in BREAKDOWN (97th %ile IV; Dealer Gamma Walls on Pro) against PMI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PMI
PACB N/M vs PMI N/M Fwd P/E
Growth & Margin Winner PMI
Op Margin -333.0% vs -248.1% ยท YoY +5.5% vs +38.6%
Momentum & Technical Winner PMI
1Y +6.7% vs +107.2% ยท 52W Pos 29% vs 34%
Options & Structure Winner PMI
BREAKDOWN (97th %ile IV) vs UNCLASSIFIED (N/A IV)
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.76
-3.83% 1D
Market Cap $571.4M
1M Return -17.76%
1Y Return +6.67%
Forward P/E N/M
Unified AI Score
60.7 / 100 BUY
Tech 59.0 Fund 57.0 Flow 57.0 Mom 60.0
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
1M Return -34.58%
1Y Return +107.24%
Forward P/E N/M
Unified AI Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PACB +6.67% PMI +107.24% Spread: +141.36 pp (PMI Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period PACB Revenue PMI Revenue PACB Op. Margin PMI Op. Margin Margin Edge
FY2018 $80M N/A -128.4% N/A PACB
FY2019 $90M N/A -110.6% N/A PACB
FY2020 $80M N/A -132.3% N/A PACB
FY2021 $130M N/A -161.2% N/A PACB
FY2022 $130M N/A -239.4% N/A PACB
FY2023 $200M N/A -166.8% N/A PACB
FY2024 $150M $0M -308.0% -312.3% PACB
FY2025 $160M $0M -346.2% -268.4% PMI

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PACB (3) vs PMI (6)
Institutional Metric PACB PMI Criterion Row Winner
Market Capitalization Scale $571.4M $17.1M Larger Scale PACB
Trailing P/E Ratio Valuation N/M 2.9x Lower Multiple PMI
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +5.5% +38.6% Higher Growth PMI
Operating Margin (TTM) Profitability -333.0% -248.1% Higher Margin PMI
Net Profit Margin Profitability -81.3% 0.0% Higher Margin PMI
Return on Equity (ROE) Capital Efficiency -929.3% 0.0% Higher ROE PMI
52-Week Range Position Momentum 29% ($1โ€“$3) 34% ($0โ€“$18) Stronger Trend PMI
Beta / 30D Volatility Risk Regime 2.27ฮฒ ยท 103% Vol 54.06ฮฒ ยท 134% Vol Lower Realized Risk PACB
Unified Institutional Score Composite Signal 60.7 / 100 (BUY) 48.4 / 100 (HOLD) Higher Composite PACB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PACB vs PMI Buy Guide
PACB BREAKDOWN
15d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 97th %ile
IV Regime Extreme (>80th %ile)
Live PACB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PMI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PACB nor PMI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.